Skip to Main content Skip to Navigation
Journal articles

Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside

Abstract : Anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitides (AAVs) are small vessel vasculitides involving predominantly ear-nose-throat, kidneys, lungs and nerves. AAVs are life-threatening diseases, especially in their most severe forms such as necrotizing crescentic glomerulonephritis (GN) and/or intra-alveolar hemorrhage. Unlike immune complex GN or anti-glomerular basement membrane GN, AAVs are classified as pauci-immune GN. However, based on recent insights from animal models, the view of AAVs as a complement-unrelated disease has been challenged. Indeed, complement activation, and especially complement alternative pathway (cAP) activation, has been shown to be determinant in AAV pathogenesis through C5a generation, a potent chemoattractant for neutrophils with priming capacities. Here, we review in vitro and in vivo data supporting the role of cAP in murine models and in human AAVs. These findings, together with the need to eradicate glucocorticoid toxicity, led to the development of an anti-C5aR molecule, CCX168, also known as avacopan. Its development and future opportunities are also discussed.
Document type :
Journal articles
Complete list of metadata

Cited literature [115 references]  Display  Hide  Download
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Thursday, March 26, 2020 - 10:19:57 AM
Last modification on : Wednesday, April 27, 2022 - 4:15:49 AM
Long-term archiving on: : Saturday, June 27, 2020 - 1:08:20 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Benoit Brilland, Anne-Sophie Garnier, Alain Chevailler, Pascale Jeannin, Jean-François Subra, et al.. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmunity Reviews, Elsevier, 2020, 19 (1), pp.102424. ⟨10.1016/j.autrev.2019.102424⟩. ⟨inserm-02519542⟩



Record views